Biogen’s $5.6 Billion Apellis Deal Is Really a Bet on Kidney Disease
The acquisition gives Biogen near-term revenue, but the more important
From Collapse to Comeback: Inside Biotech’s ‘Death-to-Rebirth’ Cycle
Layoffs Hit Biotech Hubs Hard In labs from Boston’s Kendall
MOST POPULAR
